Scandinavian Prospective Randomised Outcome Study of Hemofiltration and Hemodialysis in Incident Dialysis Patients

ISRCTN ISRCTN83264534
DOI https://doi.org/10.1186/ISRCTN83264534
Secondary identifying numbers N/A
Submission date
29/03/2006
Registration date
27/04/2006
Last edited
31/05/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Prof Anders Alvestrand
Scientific

Department of Clinical Science
Intervention and Technology
Karolinska Institutet
Stockholm
S 141 86
Sweden

Phone +46 (0)858582656
Email anders.alvestrand@klinvet.ki.se

Study information

Study designProspective, randomised, controlled, parallel group design
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymPROFIL
Study objectivesAs compared with hemodialysis (HD), on-line, predilution hemofiltration (HF) reduces the development of left ventricular hypertrophy (LVH), decreases overall morbidity, and retards the loss of residual renal function in incident dialysis patients
Ethics approval(s)Approved by the Karolinska Institute Ethics Review Board 29/12/1999, reference number: 99-292
Health condition(s) or problem(s) studiedEnd stage renal disease patients starting dialysis treatment
InterventionTwo different modes of dialysis, conventional hemodialysis (HD) versus hemofiltration (HF)
Intervention typeOther
Primary outcome measureThe objective of this study is to compare the effect of treatment with pre-dilution HF and HD, respectively, on left ventricular mass index (LVMI) during 1 to a maximum of 3 years follow up
Secondary outcome measuresTo compare the effect of HF and HD with respect to:
1. Mortality (all causes)
2. Hospitalisation (number of occasions, total number of days in hospital)
3. Blood pressure (antihypertensive drug index)
4. Dose of recombinant human erythropoietin (rHuEPO) needed to keep hemoglobin at target level
5. Infections (antibiotic drug index)
6. Serum lipids
7. Patients’ subjective evaluation of intra- and inter-dialytic symptoms
8. Residual renal function
9. Cost effectiveness
Overall study start date15/05/2000
Completion date28/02/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants48
Key inclusion criteria1. Male and female patients with chronic renal failure
2. Age ≥20 and ≤80 years
3. Dialysis treatment <3 months
4. Expected time in HD at treatment site >1 year
Key exclusion criteria1. History of myocardial infarction within 3 months
2. Unstable angina
3. Severe cardiac valvular disease
4. Severe cardiac failure (New York Heart Association [NYHA] III-IV)
5. Disseminated malignancy
6. Expected time in hemodialysis <1 year
7. Participation in another study, which may interfere with the present study
8. Unwillingness to undergo the investigations and follow-up required in the protocol
9. Access to the circulation by central venous catheter >3 months
10. Body weight ≥100 kg
Date of first enrolment15/05/2000
Date of final enrolment28/02/2006

Locations

Countries of recruitment

  • Denmark
  • Sweden

Study participating centre

Department of Clinical Science
Stockholm
S 141 86
Sweden

Sponsor information

Gambro Corporate Research (Sweden)
Industry

c/o Ingrid Ledebo
Gambro Corporate Research
Box 10101
Lund
S-220 10
Sweden

Phone +46 (0)46 16 91 76
Email ingrid.ledebo@gambro.com
ROR logo "ROR" https://ror.org/05mw5ed57

Funders

Funder type

Industry

Study monitor provided by Gambro Corporate Research; financial support to participating clinics in relation to patient enrollment came from Gambro Svenska Försäljnings AB

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/03/2011 Yes No